98 related articles for article (PubMed ID: 29327978)
1. In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial.
Geist MJP; Bardenheuer HJ; Burhenne J; Mikus G
J Palliat Med; 2018 May; 21(5):686-688. PubMed ID: 29327978
[TBL] [Abstract][Full Text] [Related]
2. Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.
Geist MJP; Siller N; Egerer G; Bardenheuer H; Burhenne J; Mikus G
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):117-122. PubMed ID: 30916851
[TBL] [Abstract][Full Text] [Related]
3. Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A.
Geist M; Bardenheuer H; Burhenne J; Mikus G
Palliat Med; 2019 Jul; 33(7):850-855. PubMed ID: 31023150
[TBL] [Abstract][Full Text] [Related]
4. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
Nassar YM; Hohmann N; Michelet R; Gottwalt K; Meid AD; Burhenne J; Huisinga W; Haefeli WE; Mikus G; Kloft C
Clin Pharmacokinet; 2022 Nov; 61(11):1595-1607. PubMed ID: 36195807
[TBL] [Abstract][Full Text] [Related]
5. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
6. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Geist MJP; Ziesenitz VC; Bardenheuer HJ; Burhenne J; Skopp G; Mikus G
Sci Rep; 2019 Oct; 9(1):14635. PubMed ID: 31601999
[TBL] [Abstract][Full Text] [Related]
7. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.
Katzenmaier S; Markert C; Mikus G
Eur J Clin Pharmacol; 2010 Nov; 66(11):1137-41. PubMed ID: 20680253
[TBL] [Abstract][Full Text] [Related]
8. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
Wiebe ST; Meid AD; Mikus G
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):527-542. PubMed ID: 32772302
[TBL] [Abstract][Full Text] [Related]
9. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
10. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.
Hohmann N; Blank A; Burhenne J; Suzuki Y; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2019 Oct; 85(10):2310-2320. PubMed ID: 31222796
[TBL] [Abstract][Full Text] [Related]
12. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
14. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
16. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
17. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
18. The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.
Brill MJ; van Rongen A; van Dongen EP; van Ramshorst B; Hazebroek EJ; Darwich AS; Rostami-Hodjegan A; Knibbe CA
Pharm Res; 2015 Dec; 32(12):3927-36. PubMed ID: 26202517
[TBL] [Abstract][Full Text] [Related]
19. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
20. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
